Premium
Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases
Author(s) -
Meserve Joseph,
Facciorusso Antonio,
Holmer Ariela K.,
Annese Vito,
Sandborn William J.,
Singh Siddharth
Publication year - 2021
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16217
Subject(s) - medicine , inflammatory bowel disease , adverse effect , discontinuation , immune system , immunology , oncology , disease , gastroenterology
Observational studies suggest that patients with autoimmune diseases may be at higher risk of immune related adverse events with immune checkpoint inhibitor therapy. 40% experience relapse of pre‐existing IBD, of whom 76% require corticosteroids and 37% require biologics to control disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom